LEADER 04546nam 22008415 450 001 9910300235703321 005 20230811005528.0 010 $a94-017-9168-6 024 7 $a10.1007/978-94-017-9168-7 035 $a(CKB)3710000000291724 035 $a(EBL)1967009 035 $a(OCoLC)908086571 035 $a(SSID)ssj0001386398 035 $a(PQKBManifestationID)11809738 035 $a(PQKBTitleCode)TC0001386398 035 $a(PQKBWorkID)11373809 035 $a(PQKB)11236991 035 $a(DE-He213)978-94-017-9168-7 035 $a(MiAaPQ)EBC1967009 035 $a(PPN)183092554 035 $a(EXLCZ)993710000000291724 100 $a20141118d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCirculating Nucleic Acids in Early Diagnosis, Prognosis and Treatment Monitoring $eAn Introduction /$fedited by Peter B. Gahan 205 $a1st ed. 2015. 210 1$aDordrecht :$cSpringer Netherlands :$cImprint: Springer,$d2015. 215 $a1 online resource (476 p.) 225 1 $aAdvances in Predictive, Preventive and Personalised Medicine,$x2211-3509 ;$v5 300 $aDescription based upon print version of record. 311 $a94-017-9167-8 320 $aIncludes bibliographical references at the end of each chapters and indexes. 327 $aPart I. BACKGROUND -- CHAPTER 1 Introduction - Brief History and the present and future status of CNAPS -- CHAPTER 2 The biology of CNAPS -- Part II. METHODOLOGY -- CHAPTER 3 Pre-analytical requirements for analysing nucleic acids from blood -- CHAPTER 4. Circulating DNA and miRNA isolation -- CHAPTER 5 Detection of genetic alterations by nucleic acid analysis: use of pcr and mass spectroscopy-based methods -- CHAPTER 6 Genomic approaches to the analysis of cell free nucleic acids -- Part III APPLICATIONS -- CHAPTER 7 CNAPS and General Medicine -- CHAPTER 8 Fetal CNAPS ? DNA/RNA -- CHAPTER 9 Circulating nucleic acids and Diabetes mellitus -- CHAPTER 10 Extracellular nucleic acids and cancer -- CHAPTER 11 Other bodily fluids as non-invasive sources of Cell-free DNA/RNA -- CHAPTER 12 CNAPS in therapy monitoring -- Part IV OTHER ASPECTCS -- CHAPTER 13 Quality Assurance -- CHAPTER 14 Societal Aspects: Ethics. 330 $aDNA and RNA fractions can be isolated from a variety of body fluids including whole blood, serum, plasma, urine, saliva and cerebrospinal fluid from both patients and healthy individuals.  Such isolates can be exploited in the early detection of clinical disorders, stratification of patients for treatment, treatment monitoring and clinical follow-up.  In addition, the use in fetal medicine allows the early detection of fetal sex, Rh factor and aneuploid disorders as well as following both fetal and premature born infant development. This volume is intended as a primer for those who are interested in entering the field of circulating nucleic acids. The areas covered in this volume include: ·      Background and general biology of circulating nucleic acids ·      Methodology ·      Applications of circulating nucleic acids ·      Quality Assurance ·      Ethics. 410 0$aAdvances in Predictive, Preventive and Personalised Medicine,$x2211-3509 ;$v5 606 $aMedicine$xResearch 606 $aBiology$xResearch 606 $aMedicine, Preventive 606 $aHealth promotion 606 $aCancer 606 $aBiomaterials 606 $aNucleic acids 606 $aMedicinal chemistry 606 $aBiomedical Research 606 $aHealth Promotion and Disease Prevention 606 $aCancer Biology 606 $aNucleic Acid 606 $aMedicinal Chemistry 615 0$aMedicine$xResearch. 615 0$aBiology$xResearch. 615 0$aMedicine, Preventive. 615 0$aHealth promotion. 615 0$aCancer. 615 0$aBiomaterials. 615 0$aNucleic acids. 615 0$aMedicinal chemistry. 615 14$aBiomedical Research. 615 24$aHealth Promotion and Disease Prevention. 615 24$aCancer Biology. 615 24$aNucleic Acid. 615 24$aMedicinal Chemistry. 676 $a612.0157 702 $aGahan$b Peter B$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910300235703321 996 $aCirculating Nucleic Acids in Early Diagnosis, Prognosis and Treatment Monitoring$91760683 997 $aUNINA